Overview

Ropivacaine Pharmacokinetics After Erector Spinae Block

Status:
Not yet recruiting
Trial end date:
2024-11-01
Target enrollment:
Participant gender:
Summary
The primary aim is to evaluate the analgesic efficacy of either technique by measuring cumulative morphine consumption in the first 24 hours after an erector spinae plane block with 2 ml/kg of ropivacaine 0.1% (2 ml/kg) or 1 ml/kg of ropivacaine 0.2%. The secondary aim of this study is to describe the pharmacokinetics of ropivacaine 0.1% and ropivacaine 0.2% after erector spinae block in children undergoing posterior spinal fusion.
Phase:
Phase 4
Details
Lead Sponsor:
McGill University Health Centre/Research Institute of the McGill University Health Centre
Treatments:
Ropivacaine